Gene Solutions and Topgen Join Forces to Advance Precision Oncology All Over China
SHANGHAI, June 12, 2025 /PRNewswire/ -- Gene Solutions has formalized a strategic collaboration with Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., a CAP-accredited laboratory with a well-established footprint across all over China.
Topgen currently operates a comprehensive next-generation sequencing (NGS) platform and serves a vast clinical network of over 1,300 hospitals. Through this collaboration, Gene Solutions will introduce several of its most advanced oncology solutions to complement and expand Topgen's existing capabilities:
These technologies will enhance Topgen's oncology portfolio and enable broader access to cutting-edge cancer screening and monitoring tools across its hospital network.
" Besides the expected enriched oncology portfolio and enhanced technology generated from the collaboration with Gene Solutions, the partnership is expected to deliver broader strategic value. For example, the co-developed technology can benefit both parties; the multi-regional clinical trial and validation on fragmentomics can accelerate the product licensing process for both parties; Moreover, our joint efforts to expand into international markets will strongly support each company's overseas business strategy." said Herry Shen, Chairman of Topgen's Board.
"Top g en's robust infrastructure and clinical reach make them an ideal partner to scale our innovations," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "This collaboration is designed to bring advanced cancer genomics to the forefront of clinical care across the extensive hospital network served by Topgen in China."
The collaboration will emphasize clinical validation, translational research, and coordinated commercialization —with the shared goal of improving cancer patient outcomes throughout the region.
Topgen Biomedical Technology is a leading innovator in precision oncology solutions in China. Headquartered in Shaoxing, Zhejiang, with R&D in Shanghai and manufacturing in Anhui, Topgen operates a national lab network spanning 30 provinces, partnering with over 1,300 hospitals and serving more than 100,000 patients. The company integrates cutting-edge technologies including qPCR, NGS, dPCR, and flow cytometry to deliver high-quality molecular diagnostics across early cancer screening, companion diagnostics, genetic testing, and disease monitoring.
Topgen's laboratories maintain rigorous compliance with CAP, GMP, and national PCR lab certifications. With 13 subsidiaries, 3 medical testing labs, and 43 in-hospital precision labs, the company combines advanced services with proprietary products under a "Service + Product" dual-engine business model. Recognized as a National High-Tech Enterprise and recipient of over 30 government innovation grants, Topgen holds 10 authorized invention patents and over 60 software and trademark IP assets.
About Gene Solutions
Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring.
With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific. Explore more information at: https://genesolutions.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
21 minutes ago
- Korea Herald
Gene Solutions and Shenzhen USK Bioscience Forge Strategic Partnership to Establish Next-Generation Sequencing Laboratory in Southern China
SINGAPORE, June 14, 2025 /PRNewswire/ -- Gene Solutions, a leading multinational biotechnology company and Shenzhen USK Bioscience Co., Ltd. (USKBio), a prominent innovator in molecular diagnostics, have entered a strategic partnership through a Memorandum of Understanding (MOU). The landmark agreement paves the way for the establishment of a state-of-the-art next generation sequencing (NGS) laboratory in southern China, advancing localized oncology diagnostics. The collaboration will leverage USKBio's existing infrastructure, and Gene Solutions' advanced next-generation AI & genomics capabilities to jointly establish a next-generation sequencing (NGS) laboratory. The lab will focus on accelerating access to early cancer detection and molecular residual disease (MRD) monitoring using AI-powered circulating tumor DNA (ctDNA) technologies, tailored to address the unique clinical needs of southern China's healthcare landscape. USKBio brings extensive expertise in Polymerase Chain Reaction (PCR) -based In Vitro Diagnostics (IVD) and Good Manufacturing Practice (GMP)-certified production capabilities. Gene Solutions contributes its leadership in NGS-based oncology applications, highlighted by its groundbreaking SPOT-MAS test — Asia's first clinically validated multi-cancer early detection (MCED) assay, validated through a prospective study of 9,024 participants. Additionally, Gene Solutions recently published a real-world MRD study involving 623 patients across six cancer types—lung, colorectal, breast, gastric, liver, and ovarian—demonstrating the clinical utility of ctDNA for monitoring treatment response and assessing recurrence risk. This partnership will focus on localizing and validating these cutting-edge technologies for the Chinese market while fostering joint R&D and production of advanced IVD medical devices. This alliance represents a major step forward in delivering accessible, high-impact, personalized cancer diagnostics to a broader population in China. "This partnership with USKBio allows us to move quickly in establishing a high-impact oncology hub in southern China," said Dr. Nguyen Hoai Nghia, CEO and Co-founder at Gene Solutions. "Together, we aim to bring early, accurate, and scalable cancer screening and diagnostics to more patients, ultimately improving cancer outcomes." "Gene Solutions and USKBio are highly complementary in their core technologies, regional markets, and business models." said Dr. Yu Dehua, CEO at USKbio. "This strategic collaboration will leverage both parties' strengths, creating strong synergies to deliver greater benefits to cancer patients across the Asia region." The partnership also includes technology transfer, technical training, and joint commercialization efforts to ensure rapid deployment and widespread adoption of these advanced genomic tools. About Shenzhen USKBio Founded in August 2015, Shenzhen USKBio is a national high-tech biological enterprise established by leading Chinese and American scientists and entrepreneurs. Specializing in in vitro molecular diagnostics, USKBio integrates R&D, production, marketing, and medical testing services, with a robust presence in IVD reagents, diagnostic instruments, and testing services. Leveraging proprietary technologies such as Udx-PCR and Udx-MSP, the company offers innovative solutions for early cancer screening, precision diagnosis, and companion diagnostics. With over 36 authorized patents and collaborations across top hospitals and testing institutions in China, USKBio is a rising leader in the global molecular diagnostics industry, dedicated to advancing precision medicine. About Gene Solutions Gene Solutions is a leading multinational biotechnology company headquartered in Asia, pioneering the integration of advanced AI and circulating tumor DNA (ctDNA) technologies to deliver innovative solutions across the cancer care continuum. Recognized for its proprietary research and CAP-accredited laboratories, the company combines multi-dimensional genomics with AI-driven analytics to transform oncology—from early detection to real-time treatment monitoring. With a strong regional presence and a commitment to empowering access to precision medicine, Gene Solutions is shaping the future of cancer diagnostics and personalized care across the Asia-Pacific.
Korea Herald
5 hours ago
- Korea Herald
Ping An Ranks 27th on Forbes' Global 2000 List
HONG KONG and SHANGHAI, June 13, 2025 /PRNewswire/ -- Ping An Insurance (Group) Company of China, Ltd. ("Ping An", the "Company" or the "Group", HKEX: 2318; SSE: 601318) has risen two spots to rank 27th on Forbes' 2025 Global 2000 list, an authoritative ranking of the world's largest public companies based on a composite score of revenue, profit, assets, and market value. Released on June 12, the latest rankings reflect Ping An's continued growth and strong performance, as the Group moved up two places from last year. Additionally, Ping An secured 5th place among Chinese companies, climbing one spot from the previous year, while maintaining its position as the highest-ranked insurance company in China. The top five Chinese companies in the 2025 rankings are Industrial and Commercial Bank of China, China Construction Bank, Agricultural Bank of China, Bank of China, and Ping An. During the period, Ping An reported revenue of US$158 billion, profit of US$17.6 billion, and total assets amounted to US$1.8 trillion. Progress driven by technology-enabled "integrated finance + health and senior care" dual-driver strategy Ping An continues to advance its technology-enabled "integrated finance + health and senior care" dual-driver strategy, driving stable growth across its core businesses. Through its integrated finance model, Ping An has strengthened its engagement with retail customers. As of the end of 2024, Ping An served 242 million retail customers, with 25.6% holding four or more contracts within the Group. Customer retention remained robust at 98.0%. The health and senior care strategy also provided differentiated advantages, with nearly 63% of Ping An's retail customers entitled to service benefits in the health and senior care ecosystem. In transforming and upgrading its core businesses, Ping An harnessed technology to reduce costs, enhance operational efficiency, and strengthen risk management. The number of service cases handled by Ping An's AI service representatives reached approximately 1.84 billion, accounting for 80% of the Group's total customer service volume in 2024. In Life insurance, 93% of policies were underwritten within seconds via smart underwriting, smart claim settlement and smart policy renewal. Moreover, Ping An P&C achieved claims savings of RMB11.94 billion through smart fraud detection, marking a year-on-year increase of 10.4%. In 2024, Ping An achieved an operating profit attributable to shareholders of the parent company of RMB121.862 billion, achieving a year-on-year increase of 9.1%. Net profit attributable to shareholders of the parent company reached RMB126.607 billion, representing a significant year-on-year increase of 47.8%. Revenue totaled RMB1,028.925 billion, up 12.6% year-on-year, while total assets reached RMB12.96 trillion, a 11.9% increase from the beginning of the year. Enhancing customer experience with the "worry-free, time-saving, and money-saving" value proposition Ping An has actively promoted its "worry-free, time-saving, and money-saving" value proposition to enhance customer experience. Under its "worry-free" services, Ping An's auto insurance now offers 82 convenient services, including roadside assistance, vehicle inspections, and chauffeur services, benefiting 236 million users of "Ping An Auto Owner" app. By the end of 2024, Ping An's home-based senior care services had expanded to cover 75 cities nationwide. For "time-saving" initiatives, 93% of the policies were underwritten within seconds through smart underwriting, smart claim settlement and smart policy renewal. Commitment to shareholder returns, communication, and value creation According to its 2024 annual report, Ping An proposed a final dividend of RMB1.62 per share in cash for 2024, bringing the total annual dividend to RMB2.55 per share, a 5% year-on-year increase. The cash dividend payout ratio based on operating profit attributable to shareholders (OPAT) was 37.9%, marking 13 consecutive years of dividend growth. The Group maintains strong communication with shareholders through annual general meetings and investor roadshows. On May 13, 2025, Ping An held its 2024 Annual General Meeting, attended by 117 shareholders. Management addressed 29 questions and suggestions raised by shareholders. Fulfilling corporate social responsibility and supporting economic development As of December 31, 2024, Ping An had invested nearly RMB10.14 trillion to support the real economy. Its green investment of insurance funds reached RMB124.712 billion, while its green loan balance amounted to RMB157.762 billion. In 2024, green insurance premium income totaled RMB 58.608 billion. Through its "Ping An Rural Communities Support", Ping An provided RMB52.014 billion in funding to promote rural industrial vitalization. In addition, MSCI upgraded Ping An's ESG rating to AA, giving it the top spot in the multi-line insurance & brokerage category in the Asia-Pacific region for three consecutive years. The Forbes Global 2000 list, published annually since 2004, evaluates publicly traded companies worldwide based on revenue, profit, assets, and market capitalization. This year's list revealed record-breaking combined figures for the top 2,000 companies, with a total revenue of US$52.9 trillion, profit of US$4.9 trillion, assets of US$242.2 trillion, and market capitalization of US$91.3 trillion. By country, the United States led with 612 companies, followed by China (including Hong Kong) with 317 companies. About Ping An Group Ping An Insurance (Group) Company of China, Ltd. (HKEx:2318 / 82318; SSE:601318) is one of the largest financial services companies in the world. It strives to become a world-leading provider of integrated finance, health and senior care services. Under the technology-driven "integrated finance + health and senior care" strategy, the Group provides professional "financial advisory, family doctor, and senior care concierge" services to its nearly 240 million retail customers. Ping An advances intelligent digital transformation and employs technologies to improve financial businesses' quality and efficiency and enhance risk management. The Group is listed on the stock exchanges in Hong Kong and Shanghai. As of the end of December 2024, Ping An had more than RMB12 trillion in total assets. The Group ranked 27 th in the Forbes Global 2000 list in 2025 and 53 rd in the Fortune Global 500 list in 2024.
Korea Herald
5 hours ago
- Korea Herald
China, U.S. should make better use of consultation mechanism to safeguard results of dialogue
BEIJING, June 13, 2025 /PRNewswire/ -- A report from People's Daily: On June 9 and 10 local time, the first meeting of China-U.S. economic and trade consultation mechanism was held in London. The two sides held candid and in-depth talks, and thoroughly exchanged views on economic and trade issues of mutual concern. They have agreed in principle the framework for implementing consensus between the two heads of state during their phone talks on June 5, as well as those reached at Geneva talks. This meeting marked a new step taken by both sides to resolve bilateral economic and trade issues through equal dialogue. Both sides acknowledge the importance of a stable China-U.S. economic and trade relationship for the economies of both countries and the global economy, and the constructive outcomes achieved by the meeting have also brought new optimism to the international community. The establishment of the China-U.S. economic and trade consultation mechanism is a major outcome of the Geneva economic and trade talks. It provides an institutional guarantee for both sides to bridge differences and deepen cooperation. During their recent phone call, the China and U.S. heads of state agreed to make good on the agreement reached in Geneva and to hold another round of meeting as soon as possible. Chinese President Xi Jinping emphasized the importance to make good use of the economic and trade consultation mechanism already in place. This meeting is an important consultation conducted under the guidance of the strategic consensus reached by the two heads of state. All sectors of both countries and the international community paid close attention to this meeting, generally believing that as the world's two largest economies, China and the U.S. are better served by cooperation than friction, and by dialogue than confrontation. There are broad expectations that both sides will continue to resolve differences through equal dialogue and consultation, contributing greater stability and certainty to the world economy. Looking back at the history of China-U.S. relations, one lesson stands out: strengthening communication and dialogue through institutional arrangements plays an important role for both sides to properly manage differences and enhance cooperation. At this meeting, the two sides engaged in candid and in-depth communication and made new progress in addressing each other's economic and trade concerns, demonstrating the effectiveness of the consultation mechanism. The sound development of China-U.S. economic and trade relations requires joint efforts from both sides. Each achievement is hard-won and should be all the more cherished and maintained. Moving forward, both sides should, in accordance with the important consensus and requirements made during the phone call between the two heads of state, further leverage the role of the China-U.S. economic and trade consultation mechanism, continuously enhance mutual understanding, reduce misperceptions, and strengthen cooperation. After decades of development, China and the U.S. have forged a pattern of complementary strengths, mutual benefits, and win-win cooperation in the economic and trade field. This progress has been driven by the joint efforts of businesses and peoples on both sides, as well as by market forces and the international division of labor. A stable China-U.S. economic and trade relationship holds profound significance not only for both countries but also for global economic stability. Economic cooperation and trade between the two countries is so huge, substantive and broad-based, involving so many players, that it is only natural for some differences to exist. Resolving differences will not be achieved overnight. It takes time, wisdom, and patience. China has approached economic and trade consultation with sincerity and principled resolve. As a responsible major country, China has taken seriously, earnestly implemented, and actively upheld the consensus reached at the Geneva talks. At this meeting, China reaffirmed its clear position of implementing the consensus and requirements made by the two heads of state and jointly safeguarding the hard-won outcomes of dialogue. The U.S. side also stated that it will work in the same direction with China, in accordance with the requirements reached during the phone call between the two heads of state, and jointly implement the "London framework." It is hoped that the U.S. will match its words with deeds by translating its commitments into concrete policies and actions - demonstrating integrity in honoring its commitments and taking meaningful steps to implement the consensus and resolve bilateral economic and trade issues through equal dialogue. Opening up is a defining feature of Chinese modernization. Regardless of changes in the external environment, China remains committed to the belief that opening up and cooperation are the right paths to high-quality development and greater mutual benefit for all. According to China's General Administration of Customs, the country's total value of goods imports and exports in yuan-denominated terms stood at 17.94 trillion yuan ($2.49 trillion) in the first five months of this year, up 2.5 percent year on year, continuing its growth momentum. Exports rose by 7.2 percent year on year, reflecting the strong resilience of China's goods trade and the steady recovery of its economy. China welcomes enterprises from all countries, including the U.S., to continue investing and operating in China and to seize the opportunities presented by its development. Both history and reality have proven that dialogue and cooperation are the only right choice for the two countries. As long as both sides move toward each other, uphold the principle of mutual respect and mutual benefit, make good use of the consultation mechanism already in place, and take concrete actions to preserve the hard-won outcomes of dialogue, the China-U.S. economic and trade relationship will stay on a steady and constructive track toward long-term progress.
